March 2026 in “International Journal of Pharmaceutics and Drug Analysis” The polyherbal emulgel is a promising treatment for rheumatoid arthritis with effective and sustained results.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
8 citations
,
July 2024 in “Children” Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
January 2026 in “Dermatologica Sinica” New and repurposed treatments are improving outcomes in dermatology.
August 2019 in “Stem cells” New treatments for hair loss, fertility, and wound healing are being explored.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
2 citations
,
November 2019 in “Journal of Medicinal Food” 12 citations
,
December 2010 in “Journal of thoracic oncology” New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.
12 citations
,
July 2020 in “International Journal of Pharmaceutics” Iron oxide nanoparticles improve skin penetration and drug release for hair loss treatment.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
November 2025 in “JPRAS Open” Exosome therapy could help with hair loss, but more research and regulation are needed.
November 2023 in “Translational Medicine Communications” Derinat may improve hair growth and quality of life in hair loss patients by reducing oxidative stress.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
July 2025 in “Journal of Investigative Dermatology” 5% ET-02 is a more effective and safe treatment for hair loss than current options.
January 2026 in “Frontiers in Pharmacology” Personalized medicine and new technologies offer promising strategies for better skin disease treatments.
July 2025 in “Journal of Investigative Dermatology” Solid Lipid Particle technology makes retinol more stable, effective, and gentle on the skin.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
January 2026 in “Regenerative Biomaterials” Advanced hydrogels can autonomously deliver drugs to treat radiation skin injuries, but challenges remain for clinical use.
54 citations
,
September 2012 in “Acta ophthalmologica” Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.
38 citations
,
September 2017 in “Journal of zoo and wildlife medicine” Oclacitinib maleate successfully treated alopecia in Andean bears.
September 2025 in “Journal of Dermatology Research Reviews & Reports” Rigenera® effectively improves hair condition in Androgenetic Alopecia, and HairMetrix® tracks progress well.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
January 2025 in “Journal of Fungi” Advanced dermoscopy techniques improve diagnosis and treatment monitoring for Kerion celsi but don't guarantee full hair regrowth.
5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
4 citations
,
January 2011 in “International Journal of Clinical Medicine” Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.
14 citations
,
May 2021 in “Marine Drugs” PDRN, derived from salmon sperm, shows promise in healing wounds, reducing inflammation, and regenerating tissues, but more research is needed to understand its mechanisms and improve its use.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
January 2018 in “대한피부과학회지” Stopping erlotinib improved severe hair loss and skin issues in a patient.
October 2025 in “Frontiers in Toxicology” A new method effectively predicts estrogen-related health effects for early screening.